Improved bioavailability of poorly soluble drugs
Maximum bioavailability is achieved by keeping the drug in the amorphous/solubilized state. This prevents the compound from "crashing out" of solution, into an insoluble crystalline form during in-vivo release in the GI tract.
In Vivo Bioavailability
- Rat Model
In vivo study in rats show improved bioavailability of two Self-Emulsifying Drug Delivery Systems (SEDDS) compared to aqueous suspension of Ontazolast (100mg/kg).
Gelucire 44/14: polyglycolized glyceride
Peceol: glyceryl mono-oleate; a pre-digested lipid
Reference data on file
In Vitro Dissolution
In vitro dissolution profiles of capsule formulations of an experimental drug* show the ability of various solubility-enhancing excipients to substantively impact the dissolution of a poorly soluble active. (USP paddle method at 50 rpm in 37º C water; 0.2% w/v polysorbate in 900 ml water).
In Vivo Bioavailability
- Dog Model
In vivo bioavailability studies in dogs show a significant bioavailability advantage of the liquid capsule dosage form, in support of the in vitro dissolution data shown above.
For more information, Contact Us
Back to R&D Home
| 
Two-Piece Capsules
